Amacathera的新型非类阿片止痛缓解药物在早期成功试验后显示出希望。 AmacaThera's new non-opioid pain relief drug shows promise after successful early trials.

Amacathera报告说,AMT-143在第一阶段临床试验中取得了成功结果,AMT-143是一种非类阿片麻醉剂,可提供长达14天的持续疼痛缓解。 AmacaThera has reported successful Phase 1 clinical trial results for AMT-143, a non-opioid anesthetic that offers up to 14 days of sustained pain relief. 这一创新旨在减少对类阿片的依赖,解决类阿片危机并提供更安全的外科手术后疼痛管理。 This innovation aims to reduce reliance on opioids, addressing the opioid crisis and providing safer post-surgery pain management. 有希望的数据吸引了投资者的兴趣,AmacaThera正在规划第二阶段的试验,同时寻求伙伴关系,以加快进入市场。 The promising data has attracted investor interest, and AmacaThera is planning for Phase 2 trials while seeking partnerships to expedite market entry.